Skip to main
KZR
KZR logo

KZR Stock Forecast & Price Target

KZR Analyst Ratings

Based on 2 analyst ratings
Hold
Strong Buy 0%
Buy 0%
Hold 100%
Sell 0%
Strong Sell 0%

Bulls say

Kezar Life Sciences is experiencing a positive shift in investor sentiment following the lifting of a partial clinical hold in its autoimmune hepatitis (AIH) program, which bolsters confidence in its risk–benefit profile for this indication. The potential full removal of the clinical hold in lupus nephritis (LN) is viewed as a significant catalyst that could enhance both investor confidence and market uptake of the company's lead product, Zetomipzomib (KZR-616). Furthermore, should the clinical hold in LN be lifted, Kezar Life Sciences may advance its development plans, thereby expanding the commercial prospects of its therapeutic pipeline.

Bears say

Kezar Life Sciences Inc. faces significant challenges, including limited financial resources that raise concerns about its ability to fund ongoing development of its pipeline candidates, Zetomipzomib and KZR-261. The company's clinical-stage status poses inherent risks, as it depends on successful trials and regulatory approvals, which are uncertain and could lead to prolonged periods without revenue. Furthermore, the competitive landscape in the biotechnology sector may hinder Kezar's potential for market penetration, given the presence of established players with more advanced therapeutic products.

KZR has been analyzed by 2 analysts, with a consensus rating of Hold. 0% of analysts recommend a Strong Buy, 0% recommend Buy, 100% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Kezar Life Sciences Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Kezar Life Sciences Inc (KZR) Forecast

Analysts have given KZR a Hold based on their latest research and market trends.

According to 2 analysts, KZR has a Hold consensus rating as of Oct 30, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Kezar Life Sciences Inc (KZR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.